JanOne Inc. Agrees to Acquire Soin Therapeutics LLC

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Adalvo Acquires Branded Pain Product Onsolis

August 2, 2022

Pharmaceuticals

Adalvo has acquired full global rights to the branded opioid analgesic Onsolis from a U.S.-based specialty pharmaceutical owner, becoming the sole and exclusive owner of the product and assuming supply and market authorisation responsibilities worldwide. The product, indicated for management of breakthrough cancer pain in opioid-tolerant patients, is sold in several EU countries and Taiwan and Adalvo intends to integrate it into its expanding branded-product portfolio.

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

Trinity Hunt Partners Makes Initial Investment in SpineOne

January 13, 2022

Healthcare Services

Trinity Hunt Partners announced a partnership and initial investment in SpineOne, a Denver-area provider of interventional pain management services, and formed a new management services organization (MSO) to support the practice. Damon Green will serve as CEO of the MSO while SpineOne founder Dr. Perry Haney remains a significant shareholder; Trinity Hunt intends to build a national interventional pain management platform through affiliations with like-minded practices.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Investcorp Acquires Sanos Group

December 14, 2020

Healthcare Services

Investcorp has acquired Sanos Group, a Denmark-based contract research organization (CRO) specialized in osteoarthritis clinical trials and site management. Investcorp said it will support Sanos' international expansion and growth into additional therapeutic areas and geographies, including expanding its research clinic network.